# US 2024/0197903 A1 · Tnf-alpha immunoconjugate therapy for the treatment of brain tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197903 A1
- Document ID: US20240197903A1
- Status: Published application
- Kind: A1
- Application number: 18/480,153
- Filed: 2023-10-03
- Published: 2024-06-20
- Earliest claimed: 2020-05-22
- Assignees: Philogen S.P.A.
- Applicants: Philogen S.P.A
- Inventors: Theresa Hemmerle
- Web page: https://patentgrep.com/patent/US20240197903A1

## CPC

- A61K 47/6813: {the drug being a peptidic cytokine, e.g. an interleukin or interferon}
- C07K 14/525: Tumour necrosis factor [TNF]
- A61K 31/175: having the group [IMAGE cpc-sch-A61K-0950.gif] , >N—C(O)—N=N— or[IMAGE cpc-sch-A61K-0951.gif] , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 38/191: {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 16/18: against material from animals or humans
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to immunoconjugates, compositions, methods and uses for treating brain tumors, especially glioma, by administration of a tumour necrosis factor alpha (TNFα) immunoconjugate.

## Claims

### Claim 1

A method of treating a brain tumor in a patient, comprising administering a TNFα immunoconjugate, the method comprising administering the TNFα immunoconjugate in combination with chemotherapy and radiotherapy to the patient, wherein the TNFα immunoconjugate comprises TNFα linked to an antibody molecule comprising L19 complementarity determining regions (CDRs), wherein the L19 CDRs are:
VH CDR1
SEQ ID NO: 1
SFSMS
VH CDR 2
SEQ ID NO: 2
SISGSSGTTYYADSVKG
VH CDR 3
SEQ ID NO: 3
PFPYFDY
VL CDR 1
SEQ ID NO: 4
RASQSVSSSFLA
VL CDR 2
SEQ ID NO: 5
YASSRAT,
and
VL CDR 3
SEQ ID NO: 6
QQTGRIPPT;
wherein the chemotherapy is temozolomide (TMZ), and wherein the brain tumor is a glioma.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of treatment according to claim 1, wherein the antibody molecule comprises the L19 VH domain SEQ ID NO: 7 and the L19 VL domain SEQ ID NO: 9.

### Claim 4 (depends on 1)

The method of treatment according to claim 1, wherein the TNFα immunoconjugate comprises TNFα linked to L19 (scFv) as set forth in SEQ ID NO: 10.

### Claim 5 (depends on 1)

The method of treatment according to claim 1, wherein the TNFα immunoconjugate has an amino acid sequence of SEQ ID NO: 13.

### Claim 6 (depends on 1)

The method of treatment according to claim 1, wherein the immunoconjugate is administered by intravenous injection.

### Claim 7 (depends on 1)

The method of treatment according to claim 1, wherein the immunoconjugate is administered by intratumoural injection or intrathecal injection.

### Claim 8 (depends on 1)

The method of treatment according to claim 1, wherein the brain tumor is selected from a Grade III/IV glioma, a Grade III/IV glioma at first relapse, an isocitrate dehydrogenase (IDH) wildtype glioma, a Grade IV glioblastoma, and a Grade IV glioblastoma at first relapse.

### Claim at position 9

-14. (canceled)

### Claim 15 (depends on 1)

The method of treatment according to claim 1, wherein temozolomide (TMZ) is administered at 75-200 mg/m2.

### Claim 16 (depends on 1)

The method of treatment according to claim 1, wherein the radiotherapy is administered at 60 Gy/30 fractions.

### Claim at position 12

-22. (canceled)

### Claim 23 (depends on 1)

The method of treatment method of claim 1, wherein the method comprises subsequent administrations of the TNFα immunoconjugate.

### Claim at position 14

-26. (canceled)

### Claim 27

A method of treating a glioma in a patient, comprising administering a TNFα immunoconjugate in combination with chemotherapy and radiotherapy to the patient, wherein the TNFα immunoconjugate comprises TNFα linked to an antibody molecule comprising L19 complementarity determining regions (CDRs), wherein the L19 CDRs are:
VH CDR1
SEQ ID NO: 1
SFSMS
VH CDR 2
SEQ ID NO: 2
SISGSSGTTYYADSVKG
VH CDR 3
SEQ ID NO: 3
PFPYFDY
VL CDR 1
SEQ ID NO: 4
RASQSVSSSFLA
VL CDR 2
SEQ ID NO: 5
YASSRAT,
and
VL CDR 3
SEQ ID NO: 6
QQTGRIPPT;
wherein the chemotherapy is temozolomide (TMZ);
wherein the antibody molecule comprises the L19 VH domain SEQ ID NO: 7 and the L19 VL domain SEQ ID NO: 9;
wherein the TNFα immunoconjugate comprises TNFα linked to L19 (scFv) as set forth in SEQ ID NO: 10 and
the TNFα immunoconjugate has an amino acid sequence of SEQ ID NO: 13.

### Claim 28 (depends on 27)

The method of claim 27, wherein the immunoconjugate is administered by a route selected from intravenous injection, intratumoural injection, and intrathecal injection.

### Claim 29 (depends on 27)

The method of claim 27, wherein said glioma is selected from a Grade III/IV glioma, a Grade III/IV glioma at first relapse, an isocitrate dehydrogenase (IDH) wildtype glioma, a newly diagnosed glioblastoma, a newly diagnosed Grade IV glioblastoma, and a Grade IV glioblastoma at first relapse.

### Claim 30 (depends on 27)

The method of claim 27, wherein temozolomide (TMZ) is administered at 75-200 mg/m2.

### Claim 31 (depends on 27)

The method of treatment according to claim 27, wherein the radiotherapy is administered at 60 Gy/30 fractions.

### Claim 32 (depends on 27)

The method of claim 27 further comprising subsequent administrations of the TNFα immunoconjugate.
